Plaquenil /00072602/


Combined with:

Enbrel
Folic Acid
Methotrexate
Prednisone

Indications and Reactions:

Role Indications Reactions
Secondary
Product Used For Unknown Indication 57.5%
Rheumatoid Arthritis 21.3%
Systemic Lupus Erythematosus 6.3%
Foetal Exposure During Pregnancy 2.5%
Hypertension 2.5%
Fibromyalgia 1.3%
Inflammation 1.3%
Juvenile Idiopathic Arthritis 1.3%
Mixed Connective Tissue Disease 1.3%
Osteoarthritis 1.3%
Osteoporosis Postmenopausal 1.3%
Psoriatic Arthropathy 1.3%
Pulmonary Hypertension 1.3%
Pneumonia 9.1%
Sinusitis 9.1%
Encephalitis 4.5%
Nausea 4.5%
Off Label Use 4.5%
Optic Nerve Disorder 4.5%
Osteopenia 4.5%
Pain 4.5%
Photopsia 4.5%
Pneumococcal Sepsis 4.5%
Pulmonary Fibrosis 4.5%
Rash Pruritic 4.5%
Rheumatoid Arthritis 4.5%
Rotator Cuff Syndrome 4.5%
Skin Sensitisation 4.5%
Synovial Cyst 4.5%
Unevaluable Event 4.5%
Upper Respiratory Tract Infection 4.5%
Urticaria 4.5%
Vision Blurred 4.5%
Concomitant
Rheumatoid Arthritis 51.6%
Product Used For Unknown Indication 34.2%
Pain 2.3%
Psoriatic Arthropathy 1.9%
Osteoporosis 1.1%
Osteoporosis Postmenopausal 1.1%
Systemic Lupus Erythematosus 1.1%
Hereditary Angioedema 0.8%
Arthritis 0.7%
Hypertension 0.7%
Psoriasis 0.6%
Arthralgia 0.5%
Depression 0.5%
Diabetes Mellitus 0.5%
Blood Pressure 0.4%
Osteoarthritis 0.4%
Asthma 0.4%
Chronic Obstructive Pulmonary Disease 0.4%
Coronary Artery Disease 0.4%
Pulmonary Hypertension 0.4%
Sinusitis 11.0%
Drug Ineffective 10.2%
Pain In Extremity 7.9%
Injection Site Pain 7.3%
Injection Site Swelling 5.9%
Rheumatoid Arthritis 5.9%
Therapeutic Response Decreased 5.6%
Injection Site Reaction 5.4%
Nasopharyngitis 4.0%
Pain 4.0%
Urinary Tract Infection 4.0%
Headache 3.7%
Nausea 3.7%
Upper Respiratory Tract Infection 3.4%
Urticaria 3.4%
Vomiting 3.1%
Weight Decreased 3.1%
Fatigue 2.8%
Injection Site Bruising 2.8%
Injection Site Warmth 2.8%

Drug Data